Thiotepa
Tepadina · Alkylator
Hemorrhagic cystitis; renally cleared.
Cytoxan · Cyclo
Oxazaphosphorine alkylator · approved 1959 · 8 citations · FAERS AKI reporting ROR 1.80 (95% CI 1.74–1.87, 3,364 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The water-retainer — a vasopressin-independent drive to hold on to free water.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Dose-related hyponatremia (not reliably quantified); hemorrhagic cystitis ~5–20%, lower with mesna prophylaxis. Reported rate: hyponatremia in 52% — 69 adults who received high-dose cyclophosphamide therapy at a single center 2010-2014 (retrospective cohort (Bonella 2017, PMID 29890094).Source: Bonella et al., Rev Fac Cien Med Univ Nac Cordoba 2017
Hyponatremia within hours of dosing; cystitis is acute.
Distilled from: “Hyponatremia within hours; cystitis acute.”
Both renal manifestations are acute and self-limited: the dilutional hyponatremia resolves with fluid restriction and sodium correction as the drug clears, and hemorrhagic cystitis settles with mesna, hydration and bladder irrigation. Unlike ifosfamide, cyclophosphamide is not a driver of chronic tubulopathy or CKD — it is the less urotoxic of the two oxazaphosphorines.PMID 9415661 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsGermline / pharmacogenomic variants that shift an individual's risk of this agent's kidney injury. Research-grade — not routine clinical testing.
In children receiving cyclophosphamide-based myeloablative conditioning before allogeneic HSCT, carrying functional alleles at both GSTM1 and CYP2C9 was associated with ~4.8-fold higher risk of hemorrhagic cystitis (HR 4.8, 95% CI 1.3-18.4, p=0.02) vs dysfunctional/null genotypes, supporting pre-emptive genotyping to guide uroprotective prophylaxis. PMID 28744217 (opens PubMed in a new tab)
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
SIADH with hyponatremia is a recognized complication of high-dose cyclophosphamide (direct collecting-duct water retention); described at case/mechanistic level with no cohort incidence denominator. PMID 10864220 (opens PubMed in a new tab)
Hemorrhagic cystitis in 22/805 (2.7%) cyclophosphamide-treated systemic necrotizing vasculitis patients over 4,230 patient-years; risk driven by cumulative dose and oral (vs IV) administration. Higher and dose-limiting in high-dose/conditioning settings without mesna.
Tap a signature to trace where it strikes the nephron.
Representative incidence
SIADH / Hyponatremia strikes: Distal Tubule / Collecting Duct.
SIADH / Hyponatremia
Inappropriate water retention at the collecting duct — high-dose cyclophosphamide.
Prodrug converted to phosphoramide mustard, cross-linking DNA. Lymphomas, breast cancer, autoimmune disease and transplant conditioning.
Class-level context for the major non-renal toxicities of the Oxazaphosphorine alkylator class.
Hematologic
Cytopenias, thrombosis, TMA
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
5 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Monitor for toxicity in patients with moderate and severe renal impairment. ( 8.6 , 12.3 )
Kidney rows of the label's dosage tables
From the Frindovyx label (Aug 2026) · DailyMed
No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 179,391 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
36,268 of 179,391 reports
Reported with hospitalization
64,811 of 179,391 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 34,802 of the 179,391 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Cyclophosphamide sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Tepadina · Alkylator
Hemorrhagic cystitis; renally cleared.
Alkeran · Alkylator
SIADH in high-dose myeloma conditioning; renally cleared.
Temodar · Alkylator
Occasional SIADH; generally renally well tolerated.
Leukeran · Alkylating agent (nitrogen mustard)
Minimal direct nephrotoxicity; rare drug-associated SIADH/hyponatremia is the kidney-relevant signal.
Velban · Vinca alkaloid
SIADH and rare Raynaud/vascular events.
Oncovin · Vinca alkaloid
SIADH → hyponatremia.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Cyclophosphamide’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Cyclophosphamide; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 200 clinical records among the 300 most-relevant of 4,486 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.